Holly Martin

Articles by Holly Martin

62 Integrating Dose Modifications for Effective Management of HR+, HER2– Early Breast Cancer With Abemaciclib

ByVanna Dest,Gineesha Abraham,Michelle Corso,Mattia Garutti,Katheryn Moreira,Holly Martin,Victoria J. Stefaniak,Monique Coersmeyer,Eriko Tokunaga

June 17th 2026

This review of monarchE and TRADE data demonstrates that abemaciclib dose modifications manage treatment-related adverse events without compromising efficacy in high-risk HR+, HER2− early breast cancer.

15 Concurrent Use of Abemaciclib and Radiation Therapy (RT) Among Patients With HR+, HER2– Metastatic Breast Cancer (MBC): Real-World Utilization and Safety

ByWambui Gathirua-Mwangi,Sangmi Kim,Holly Martin,Tasneem Lokhandwala,Shen Zheng,Eileen Farrelly,Sarah Rybowski

August 13th 2024

Holly Martin

Articles by Holly Martin

62 Integrating Dose Modifications for Effective Management of HR+, HER2– Early Breast Cancer With Abemaciclib

15 Concurrent Use of Abemaciclib and Radiation Therapy (RT) Among Patients With HR+, HER2– Metastatic Breast Cancer (MBC): Real-World Utilization and Safety

Latest Updated Articles

Trending on CancerNetwork

Where Does LAG-3/PD-1 Inhibition Fit In PD-1–Refractory Hodgkin Lymphoma?

VS-7375 Exhibits Activity in KRAS G12D–Mutated Solid Tumors

Offering Hope and Support Toward the Cancer Survivorship Journey

GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations

Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications